Rationale: Adenoid cystic carcinoma (ACC) often occurs in the major and minor salivary glands and other sites containing secretory glands, while ACC of the Bartholin’s gland (BG-ACC) in the vulva is rare and easily misdiagnosed. Patient concerns: A 58-year-old female was referred to our hospital for further valuation of a mass occurring on the left side of her vulva. In the other hospital, the beginning of the period, local ultrasound showed a vulva mass, which was suspected to be a Bartholin’s gland cyst. Mixed neoplasms were considered in some biopsies. When transferred to our hospital, virtuous tumors were considered by ultrasound and magnetic resonance imaging. Pathology initially considered benign hyperplastic active tumor or borderline tumor. Diagnoses: Histological, immunochemical, and molecular tests confirmed a diagnosis of BG-ACC, negative surgical margin, without lymphatic metastasis. Interventions: Extended excision of the mass at left labia majora plus left inguinal lymph node dissection was performed. Outcomes: The patient received surgery therapy, no recurrence was observed during a 18-month follow-up period. Lessons: Due to its lack of specific characteristics in clinical, ultrasound and imaging, it is easy to be misdiagnosed, Due to its rarity and nonspecific clinical, radiologic and ultrasonographic manifestations, BG-ACC can be easily misdiagnosed. And its pathomorphological features overlap with other benign and malignant tumors occurring at vulva, BG-ACC can be easily misdiagnosed, and diagnosis by puncture biopsy is extremely difficult. Use of paraffin sections to identify tumor growth characteristics, combined with immunohistochemical findings, is the key to the diagnosis of ACC. In rare sites, MYB gene split are helpful in making a definite diagnosis.
20 February 2025 in Gynecologic and Obstetric Investigation
Objectives: Endometriosis (EM) is a chronic disease severely impacting reproductive health, with its exact cause still unclear. In-depth understanding of the etiology and pathogenesis of EM from the perspective of genetics and exploring individualized treatment strategies can improve the health and quality of life of patients. Design: This study combined genetic data analysis with experimental validation to provide novel biomarkers and drug targets for the diagnosis and treatment of EM. Participants/Materials, Setting, and Methods: Whole blood cis-expression quantitative trait loci (eQTL) data were used as exposure data, and data from the FinnGen database EM1-2 and EM3-4 were used as outcomes. Summary-data-based Mendelian randomization (SMR) methods were used to select genes with causal relationship to the disease. These genes were validated through bioinformatics analysis and real-time quantitative polymerase chain reaction (RT-qPCR) analysis of clinical samples, and potential diagnostic and drug targets were screened through colocalization and molecular docking. Results: Through SMR analysis, seven genes were selected as potential diagnostic markers of EM, namely Eukaryotic Elongation Factor, Selenocysteine-TRNA-Specific (EEFSEC), INO80 complex subunit E (INO80E), RAP1 GTPase-activating protein (RAP1GAP), Lipid Droplet-Associated Hydrolase (LDAH), Ring Finger And SPRY Domain Containing 1 (RSPRY1), HLA Complex Group 22 (Non-Protein Coding) (HCG22), and Adenosine Kinase (ADK). Colocalization analysis showed that EEFSEC, HCG22, INO80E, and RSPRY1 could be used as potential drug targets. Limitations: SMR is limited by dependence on publicly available summary data, potential confounding biases in genetic variant-phenotype associations, the presence of underlying horizontal pleiotropy, and issues related to insufficient statistical power. Colocalization analysis cannot assess undiscovered genetic variants. The in vitro experiments in this study utilized clinical samples but were validated only at the expression level. The accuracy of molecular docking analysis largely depends on the quality of protein structures and ligands. Conclusions: The study identifies potential diagnostic markers and drug targets for EM from a genetic perspective, providing new directions for drug development and precision medicine for EM treatment.
Rationale: Ovarian granulosa cell tumor is a rare sex cord-stromal malignancy (2%–5% of ovarian carcinomas). Its diagnosis and management become particularly challenging when this tumor is associated with pregnancy and complicated by intraoperative rupture. Patient concerns: A 40-year-old multiparous woman underwent emergency cesarean section for fetal distress at 39 weeks. A previously unidentified 2 cm left ovarian cyst was discovered and incidentally ruptured during cystectomy. Diagnoses: Histopathology analysis revealed the diffuse nests of monomorphic cells exhibiting nuclear grooves and Call-Exner bodies. Immunohistochemistry analysis was positive for FOXL2, inhibin, and vimentin, confirming adult granulosa cell tumor classified as International Federation of Gynecology and Obstetrics IC1. Interventions: Initial cystectomy was performed. The patient subsequently underwent a postpartum fertility-sparing, including laparoscopic staging procedure, which included left salpingo-oophorectomy and omentectomy; no residual disease was identified. Outcomes: No evidence of recurrence was detected during follow-up. The patient retained fertility potential and declined adjuvant therapy. Lessons: Systematic adnexal evaluation during cesarean sections is essential for detecting occult ovarian neoplasms, emphasizing the importance of multidisciplinary collaboration and accessible intraoperative frozen section analysis, particularly in resource-limited settings.